Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment,
crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose
levels of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS
MDI), 90 μg and 180 μg, compared with placebo for AS MDI (hereafter referred to as Placebo
MDI) and open-label Proventil® hydrofluoroalkane (HFA; hereafter referred to as Proventil) 90
μg and 180 μg in adult and adolescent subjects with mild to moderate asthma. This study
design utilizes 10 treatment sequences.